



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/806,296
Applicant : Jaime A. Rabi
Filed : March 22, 2004
T.C./A.U. : 1623
Examiner : Ganapathy Krishnan

Docket No. : 06171.105107 (IDX 1012 C)
Customer No. : 20786

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

July 17, 2006

Information Disclosure Statement

Sir:


Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publications listed on the accompanying PTO-1449. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

Although no fee is believed due, the Commissioner is hereby authorized to charge any deficiency associated with this paper to Deposit Account No. 11-0980.

KING & SPALDING
1180 Peachtree Street
Atlanta, Georgia 30309-3521
404-572-3541 (Telephone)
404-572-5134 (Facsimile)

Respectfully submitted,

Sherry M. Knowles
Sherry M. Knowles 36,174
Sherry M. Knowles
Registration No. 33,052



Supplement to form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **1** of **3****Complete if Known**

| | |
|------------------------|------------------------|
| Application Number | 10/806,296 |
| Filing Date | March 22, 2004 |
| First Named Inventor | Rabi, J.A. |
| Group Art Unit | 1623 |
| Examiner Name | Ganapathy Krishnan |
| Attorney Docket Number | 06171.105107 IDX 1012C |

3478701 2.DOC 1

U.S. PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages/Relevant Figures Appear |
|------------------------|--------------------------|----------------------|-------------------------|--|--|--|
| | | Number | Kind Code (if known) | | | |
| | AA | 3,891,623 | A | Vorbruggen <i>et al.</i> | 06-24-1975 | |
| | AB | 4,754,026 | A | Kawada <i>et al.</i> | 06-28-1988 | |
| | AC | 4,957,924 | A | Beauchamp | 09-18-1990 | |
| | AD | 5,144,018 | A | Kuzuhara <i>et al.</i> | 09-01-1992 | |
| | AE | 5,565,438 | A | Chu <i>et al.</i> | 10-15-1996 | |
| | AF | 5,567,688 | A | Chu <i>et al.</i> | 10-23-1996 | |
| | AG | 5,587,362 | A | Chu <i>et al.</i> | 12-24-1996 | |
| | AH | 6,153,594 | A | Børretzen <i>et al.</i> | 11-28-2000 | |
| | AI | 6,248,878 | B1 | Matulic-Adamic <i>et al.</i> | 06-19-2001 | |
| | AJ | 6,271,212 | B1 | Chu <i>et al.</i> | 08-07-2001 | |
| | AK | 6,395,716 | B1 | Gosselin <i>et al.</i> | 05-28-2002 | |
| | AL | 6,444,652 | B1 | Gosselin <i>et al.</i> | 09-03-2002 | |
| | AM | 2003-0050229 | A1 | Sommadossi <i>et al.</i> | 03-13-2003 | |
| | AN | 6,566,344 | B1 | Gosselin <i>et al.</i> | 05-20-2003 | |
| | AO | 6,569,837 | B1 | Gosselin <i>et al.</i> | 05-27-2003 | |
| | AP | 2003-0083306 | A1 | Imbach <i>et al.</i> | 05-01-2003 | |
| | AQ | 2004-0006002 | A1 | Sommadossi <i>et al.</i> | 01-08-2004 | |
| | | 2005/0020825 | | Storer <i>et al.</i> | 01-27-2005 | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages/ Relevant Figures Appear | T ⁶ |
|------------------------|--------------------------|-------------------------|------------|--------------------------------------|---|---|--|----------------|
| | | Office ³ | Number | Kind Code ² (if known) | | | | |
| | AR | DD | 0,140,254 | Z | Akad. Wissenschaft der DDR Zentralinstitut für Molekularbiologie | 02-20-1980 | | |
| | AS | DE | 42 24 737 | A1 | Prof. Dr. Herbert Schott | 02-03-1994 | with English abstract | |
| | AT | EP | 0 352 248 | A1 | Johansson <i>et al.</i> | 01-24-1990 | | |
| | AU | JP | 62-93645 | A | Jpn. Kokai Tokkyo Koho | 10-21-1994 | machine translation | |
| | AV | JP | 07224081 | A2 | Kobayashi Perfumery Co. | 08-22-1995 | English translation | |
| | AW | JP | 2000290289 | A2 | Mitsui Chemicals Inc. | 10-17-2000 | English translation | |
| | AX | WO | 95/07287 | A1 | CNRS | 03-16-1995 | | |
| | AY | WO | 96/11204 | A1 | Max Delbrück Centr. Mol. Med. | 04-18-1996 | with English abstract | |
| | AZ | WO | 96/13512 | A2 | Genencor Int'l; Lipitek | 05-09-1996 | | |
| | AAA | WO | 96/40164 | A1 | Emory U.; UAB Res.Found.; CNRS | 12-19-1996 | | |

3478701

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|------------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/806,296 |
| | | | | Filing Date | March 22, 2004 |
| | | | | First Named Inventor | Rabi, J.A. |
| | | | | Group Art Unit | 1623 |
| | | | | Examiner Name | Ganapathy Krishnan |
| | | | | Attorney Docket Number | 06171.105107 IDX 1012C |
| Sheet | 2 | of | 3 | | |

3478701 2.DOC

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|--|----------|----|---|---|
| Examiner Initials * | Cite No. ¹ | Foreign Patent Document Office ³ Number Kind Code ² (if known) | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
| | BA | WO | 00/09531 | A2 | Novirio Pharm.; CNRS | 02-24-2000 |
| | BB | WO | 01/90121 | A2 | Novirio; Univ.... Cagliari | 11-29-2000 |
| | BC | WO | 01/96353 | A2 | Novirio Pharm.; C.N.R.S. | 21-20-2001 |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| | BD | BENZARIA, S., <i>et al.</i> , "Synthesis of potential prodrugs of b-4-L-dC, a potent and selective anti-HBV agent," <i>Antiviral Res.</i> , 50:A79 (2001). [Abstract no. 137]. | |
| | BE | BLOCH, A., <i>et al.</i> , "The Role Of The 5'-Hydroxyl Group Of Adenosine In Determining Substrate Specificity For Adenosine Deaminase," <i>J. Med. Chem.</i> , 10(5):908-12 (September 1967). | |
| | BF | BRYANT, M.L., <i>et al.</i> , "Antiviral L-nucleosides specific for hepatitis B virus infection," <i>Antimicrob. Agents Chemother.</i> , 45(1):229-235 (January 2001). | |
| | BG | BUDAVARI, <i>et al.</i> , Eds., <i>The Merck Index</i> , 12th Edition, Entry no. 10039, p. 10044. | |
| | BH | CAVELIER, F., <i>et al.</i> , "Studies of selective Boc removal in the presence of silyl ethers," <i>Tetrahedron Letters</i> , 37:5131-5134 (1996). | |
| | BI | CRETTON-SCOTT, E., <i>et al.</i> , "Pharmacokinetics of β -L-2'-deoxycytidine prodrugs in monkeys," <i>Antiviral Res.</i> , 50:A44 (2001) [Abstract no. 16]. | |
| | BJ | DAVISSON, V.J., <i>et al.</i> , "Synthesis of Nucleotide 5'-Diphosphates from 5'-O-Tosyl Nucleosides," <i>J. Org. Chem.</i> , 52(9):1794-1801 (1987). | |
| | BK | FOX, J.J., <i>et al.</i> , "Thiolation of nucleosides. II. Synthesis of 5-methyl-2'-deoxycytidine and related pyrimidine nucleosides," <i>J. Am. Chem. Soc.</i> , 81:178-187 (1959). | |
| | BL | HOARD, D.E., <i>et al.</i> , "Conversion of Mono- and Oligodeoxyribonucleotides to 5'-Triphosphates," <i>J. Am. Chem. Soc.</i> , 87(8):1785-1788 (April 20, 1965). | |
| | BM | HOLY, A., "Nucleic Acid Components and Their Analogs. CLIII. Preparation of 2'-deoxy-L-Ribonucleosides of the Pyrimidine Series," <i>Collect. Czech. Chem. Commun.</i> , 37(12):4072-4087 (1972). | |
| | BN | HUBBARD, A.J. <i>et al.</i> , "An Investigation by 1H NMR Spectroscopy Into the Factors Determining the β : α Ratio of the Product in 2'-Deoxynucleoside Synthesis," <i>Nucleic Acids Research</i> , 12(7): 6827-6837(1984) | |
| | BO | IMAI, K., <i>et al.</i> , "Studies on Phosphorylation. IV. Selective Phosphorylation of the Primary Hydroxyl Group in Nucleosides," <i>J. Org. Chem.</i> , 34(6):1547-1550 (June 1969). | |
| | BP | KANEKO, M., <i>et al.</i> , "A convenient synthesis of cytosine nucleosides," <i>Chem. Pharm. Bull.</i> , 20:1050-1053 (1972). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

| | |
|------------------------|------------------------|
| Application Number | 10/806,296 |
| Filing Date | March 22, 2004 |
| First Named Inventor | Rabi, J.A. |
| Group Art Unit | 1623 |
| Examiner Name | Ganapathy Krishnan |
| Attorney Docket Number | 06171.105107 IDX 1012C |

3478701 2.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | CA | KERR, S.G., <i>et al.</i> , "N4-(dialkylamino)methylene derivatives of 2'-deoxycytidine and arabinocytidine: physicochemical studies for potential prodrug applications," <i>J. Pharm. Sci.</i> , 83(4):582-586 (April 1994). | |
| | CB | LIN, T.-S., <i>et al.</i> , "Synthesis of Several Pyrimidine L-Nucleoside Analogues as Potential Antiviral Agents," <i>Tetrahedron Letters</i> , 51(4):1055-1068 (1995). | |
| | CC | LUH, T.-Y., <i>et al.</i> , "A convenient method for the selective esterification of amino-alcohols," <i>Synthetic Communications</i> , 8(5):327-333 (1978). | |
| | CD | MAGA, Giovanni, <i>et al.</i> , "Lack of stereospecificity of suid pseudorabies virus thymidine kinase," <i>Biochem. J.</i> , 294(2):381-385 (1993). | |
| | CE | McCORMICK, J., <i>et al.</i> , "Structure and total synthesis of HF-7, a neuroactive glyconucleoside disulfate from the funnel-web spider <i>Hololena curta</i> ," <i>J. Am. Chem. Soc.</i> , 121(24):5661-5664 (1999). | |
| | CF | PIERRA, C., <i>et al.</i> , "Comparative studies of selected potential prodrugs of β -L-dC, a potent and selective anti-HBV agent," <i>Antiviral Res.</i> , 50:A79 (2001). [Abstract no. 138]. | |
| | CG | STANDRING, D.N., <i>et al.</i> , "Antiviral beta-L-nucleosides specific for hepatitis B virus infection," <i>Antiviral Chem. & Chemother.</i> , 12 (Suppl. 1):119-129 (2001). | |
| | CH | TANG, X.-Q., <i>et al.</i> , "2'-C-Branched ribonucleosides: Synthesis of the phosphoramidite derivatives of 2'-C-b-methylcytidine and their incorporation into oligonucleotides," <i>J. Org. Chem.</i> , 64(3):747-754 (1999). | |
| | CI | TYRSTED, G., <i>et al.</i> , "Inhibition of the synthesis of 5-phosphoribosyl-1-pyrophosphate by 3'-deoxy-adenosine and structurally related nucleoside analogs," <i>Biochim. Biophys. Acta.</i> , 155(2):619-622 (February 26, 1968). | |
| | CJ | VERRI, A., <i>et al.</i> , "Lack of enantiospecificity of human 2'-deoxycytidine kinase: relevance for the activation of β -L-deoxycytidine analogs as antineoplastic and antiviral agents," <i>Molecular Pharmacology</i> , 51(1):132-138 (January 1997). | |
| | CK | VERRI, A., <i>et al.</i> , "Relaxed Enantioselectivity of Human Mitochondrial Thymidine Kinase and Chemotherapeutic Uses of L-Nucleoside Analogues," <i>Biochem. J.</i> , 328(1):317-320 (November 15, 1997). | |
| | CL | Von JANTA-LIPINSKI, M., <i>et al.</i> , "Newly Synthesized L-Enantiomers of 3'-Fluoro-Modified β -2'-Deoxyribonucleoside 5'-Triphosphates Inhibit Hepatitis B DNA Polymerase but not the Five Cellular DNA Polymerases α , β , γ , δ , and ϵ Nor HIV-1 Reverse Transcriptase," <i>J. Medicinal Chemistry</i> , 41(12):2040-2046 (May 21, 1998). | |
| | CM | ZEDECK, M.S., <i>et al.</i> , "Inhibition of the steroid-induced synthesis of D5-3-ketosteroid isomerase in <i>Pseudomonas testosterone</i> by a new purine deoxyribonucleoside analog: 6-chloro-8-aza-9-cyclopentylpurine," <i>Mol. Pharmacol.</i> , 3(4):386-395 (1967). | |
| | CN | ZHANG, W., <i>et al.</i> , "Removal of silyl protecting groups from hydroxyl functions with ammonium fluoride in methanol," <i>Tetrahedron Letters</i> , 33:1177-1180 (1992). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.